Table 4 Treatment-related adverse events of GC and RC48-ADC
Adverse event | Any grade | Grade ≥ 3 | |||||
|---|---|---|---|---|---|---|---|
GC(N = 83) | RC48(N = 42) | P | GC(N = 83) | RC48(N = 42) | P | ||
Number of patients (percent) | |||||||
Any adverse event | 77 (92.8%) | 28(66.7%) |  < 0.001 | 23(27.7%) | 4(9.5%) | 0.020 | |
Peripheral sensory neuropathy | 9 (10.8%) | 7(16.7%) | 0.357 | 0 | 0 | - | |
Alopecia | 6(7.2%) | 14(33.3%) |  < 0.001 | 0 | 0 | - | |
Skin reactions | 4(4.8%) | 2(4.8%) | 1.000 | 2(2.4%) | 0 | 0.550 | |
Fever | 3(3.6%) | 1(2.4%) | 1.000 | 0 | 0 | - | |
Fatigue | 51(61.4%) | 11(26.2%) |  < 0.001 | 9(10.8%) | 0 | 0.028 | |
Gastrointestinal reaction | 67(80.7%) | 8(19.0%) |  < 0.001 | 12(14.5%) | 1(2.4%) | 0.037 | |
Anemia | 41(49.4%) | 11(26.2%) | 0.013 | 17(20.5%) | 2(4.8%) | 0.021 | |
Leukopenia | 36(43.4%) | 7(16.7%) | 0.003 | 6(7.2%) | 2(4.8%) | 0.595 | |
Thrombocytopenia | 21(25.3%) | 3(7.1%) | 0.015 | 3(3.6%) | 0 | 0.550 | |
Liver function abnormalities | 35(42.2%) | 20(47.6%) | 0.562 | 4(4.8%) | 1(2.4%) | 0.663 | |
Renal function abnormalities | 16(19.3%) | 2(4.8%) | 0.029 | 4(4.8%) | 0 | 0.299 | |